In a report issued on October 26, Matt Phipps from William Blair maintained a Buy rating on Chinook Therapeutics (KDNY). The company’s shares closed last Friday at $11.24.
According to TipRanks.com, Phipps ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.9% and a 35.9% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Atara Biotherapeutics.
Currently, the analyst consensus on Chinook Therapeutics is a Strong Buy with an average price target of $27.25, which is a 129.4% upside from current levels. In a report issued on October 19, Oppenheimer also upgraded the stock to Buy with a $25.00 price target.
See today’s analyst top recommended stocks >>
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KDNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company’s platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
